Clinical Trials Browser

Malignant Solid Neoplasm

Triple Negative Breast Neoplasms

Lymphoma, Multiple Myeloma

Lymphoma, Multiple Myeloma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Ovarian Neoplasms, Endometrial Neoplasms

Lymphoma, Non-Hodgkin

Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Lymphoma, Follicular, Endometrial Neoplasms

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin

Lymphoma, Non-Hodgkin

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Lymphoma, Non-Hodgkin

Lymphoma, Mantle-Cell

Lymphoma, T-Cell, Peripheral

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Carcinoma, Endometrioid

Digestive System Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Hepatic Insufficiency, Renal Insufficiency

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

CHRONOS-3

COD

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Study of Copanlisib and Ketogenic Diet

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

CHRONOS-4

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

CHRONOS-2

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Study of Copanlisib in Hepatic or Renal Impairment

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)